Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)
Concept/Terms
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in Harvard Catalyst Profiles by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 2 | 1 | 3 |
| 1993 | 8 | 0 | 8 |
| 1994 | 5 | 2 | 7 |
| 1995 | 4 | 4 | 8 |
| 1996 | 9 | 0 | 9 |
| 1997 | 7 | 2 | 9 |
| 1998 | 7 | 1 | 8 |
| 1999 | 6 | 0 | 6 |
| 2000 | 6 | 2 | 8 |
| 2001 | 11 | 1 | 12 |
| 2002 | 10 | 3 | 13 |
| 2003 | 19 | 2 | 21 |
| 2004 | 9 | 0 | 9 |
| 2005 | 7 | 3 | 10 |
| 2006 | 10 | 1 | 11 |
| 2007 | 11 | 0 | 11 |
| 2008 | 16 | 0 | 16 |
| 2009 | 11 | 3 | 14 |
| 2010 | 18 | 1 | 19 |
| 2011 | 11 | 0 | 11 |
| 2012 | 18 | 0 | 18 |
| 2013 | 23 | 2 | 25 |
| 2014 | 15 | 0 | 15 |
| 2015 | 21 | 3 | 24 |
| 2016 | 20 | 3 | 23 |
| 2017 | 24 | 2 | 26 |
| 2018 | 24 | 1 | 25 |
| 2019 | 25 | 2 | 27 |
| 2020 | 21 | 2 | 23 |
| 2021 | 24 | 0 | 24 |
| 2022 | 3 | 0 | 3 |
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? Drugs Aging. 2022 Apr; 39(4):271-284.
-
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022 02; 126(3):430-439.
-
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data. Anticancer Drugs. 2022 01 01; 33(1):e61-e68.
-
Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes. Clin Genitourin Cancer. 2022 Apr; 20(2):139-147.
-
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clin Genitourin Cancer. 2022 Apr; 20(2):165-175.
-
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 03 15; 128(6):1194-1205.
-
Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database. Clin Genitourin Cancer. 2022 Apr; 20(2):e135-e139.
-
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46.
-
Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain. Int J Radiat Oncol Biol Phys. 2021 09 01; 111(1):113-116.
-
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist. 2021 12; 26(12):1017-1025.